Interpreting the Findings From the Recent PCSK9 Monoclonal Antibody Cardiovascular Outcomes Trials.

Wong ND, Shapiro MD

Host defense triggers rapid adaptive radiation in experimentally evolving parasites.

Bush SE, Villa SM, Altuna JC, Johnson KP, Shapiro MD, Clayton DH

A four-questions perspective on public information use in sticklebacks (Gasterosteidae).

Webster MM, Chouinard-Thuly L, Herczeg G, Kitano J, Riley R, Rogers S, Shapiro MD, Shikano T, Laland KN

Relationship Between Low-Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab.

Shapiro MD, Minnier J, Tavori H, Kassahun H, Flower A, Somaratne R, Fazio S

Brief Commentary: Marijuana and Cardiovascular Disease-What Should We Tell Patients?

Kaufman TM, Fazio S, Shapiro MD

Application of PCSK9 Inhibitors in Practice.

Kaufman TM, Warden BA, Minnier J, Miles JR, Duell PB, Purnell JQ, Wojcik C, Fazio S, Shapiro MD

The Intersection of Diabetes and Cardiovascular Disease-A Focus on New Therapies.

Dhindsa DS, Sandesara PB, Shapiro MD

Biologic bases of residual risk of cardiovascular events: A flawed concept.

Shapiro MD, Fazio S

Medication-based versus target-based lipid management.

Fazio S, Shapiro MD

Taking a look under the hood"-imaging the phenotypic heterogeneity of familial hypercholesterolemia.

Shapiro MD, Fazio S